M&A Deal Summary |
|
---|---|
Date | 2016-12-02 |
Target | Vascular Solutions |
Sector | Medical Products |
Buyer(s) | Teleflex |
Deal Type | Add-on Acquisition |
Deal Value | 1.0B USD |
Advisor(s) | Guggenheim Securities (Financial) Dorsey & Whitney (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1943 |
Sector | Medical Products |
Employees | 14,500 |
Revenue | 3.0B USD (2023) |
Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. The Company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Teleflex markets and sells its products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors. Teleflex was founded in 1943 and is based in Wayne, Pennsylvania.
DEAL STATS | # |
---|---|
Overall | 22 of 28 |
Sector (Medical Products) | 18 of 21 |
Type (Add-on Acquisition) | 19 of 24 |
State (Minnesota) | 1 of 1 |
Country (United States) | 14 of 19 |
Year (2016) | 2 of 2 |
Size (of disclosed) | 3 of 13 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-01-11 |
Nostix
Boulder, Colorado, United States Nostix LLC is a medical technology company that develops and commercializes differentiated PICC tip placement confirmation and navigation products. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-09-05 |
NeoTract
Pleasanton, California, United States NeoTract, Inc. is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift® System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. Performed primarily through a transurethral outpatient procedure, the UroLift® System delivers permanent implants that hold open the urethra, reducing the prostate obstruction without cutting, heating, or removing prostate tissue. |
Buy | $1.1B |